PBYI
Puma Biotechnology Inc

6,881
Mkt Cap
$320.99M
Volume
647,413.00
52W High
$6.66
52W Low
$2.58
PE Ratio
8.91
PBYI Fundamentals
Price
$6.60
Prev Close
$6.37
Open
$6.34
50D MA
$5.57
Beta
0.87
Avg. Volume
383,139.86
EPS (Annual)
$0.6166
P/B
2.88
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
Zacks Research Issues Pessimistic Forecast for PBYI Earnings
Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Equities researchers at Zacks Research decreased their Q1 2027 earnings estimates for Puma Biotechnology in a research report issued to clients...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Ritholtz Wealth Management Raises Stake in Puma Biotechnology, Inc. $PBYI
Ritholtz Wealth Management lifted its holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 139.0% during the third quarter, according to its most recent disclosure with the Securities...
MarketBeat·3d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Share Price Crosses Above 200 Day Moving Average - What's Next?
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200-Day Moving Average - What's Next...
MarketBeat·5d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200 Day Moving Average - Here's What Happened
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving Average - Time to Sell...
MarketBeat·21d ago
News Placeholder
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday...
Business Wire·29d ago
News Placeholder
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
Zacks·1mo ago
News Placeholder
Acorn Capital Advisors LLC Has $14.17 Million Stake in Puma Biotechnology, Inc. $PBYI
Acorn Capital Advisors LLC grew its position in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 4.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·1mo ago
News Placeholder
American Century Companies Inc. Grows Stake in Puma Biotechnology, Inc. $PBYI
American Century Companies Inc. grew its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 16.8% in the 2nd quarter, according to the company in its most recent 13F filing...
MarketBeat·1mo ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200-Day Moving Average - Time to Sell...
MarketBeat·2mo ago
News Placeholder
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
Zacks·2mo ago
<
1
2
...
>

Latest PBYI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.